US government awards Novavax $1.6 billion for coronavirus vaccine | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Wednesday
September 27, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
WEDNESDAY, SEPTEMBER 27, 2023
US government awards Novavax $1.6 billion for coronavirus vaccine

Coronavirus chronicle

Reuters
07 July, 2020, 05:05 pm
Last modified: 07 July, 2020, 05:07 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit
  • Britain approves Valneva's easy-to-store Covid shot
  • More funds incoming from dev partners for vaccine purchase

US government awards Novavax $1.6 billion for coronavirus vaccine

It will also cover the cost of running a large Phase III trial - the final stage of human testing, which could begin as early as October

Reuters
07 July, 2020, 05:05 pm
Last modified: 07 July, 2020, 05:07 pm
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo

The US government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.

The award is the biggest yet from "Operation Warp Speed", the White House program aimed at accelerating access to vaccines and treatments to fight the coronavirus that causes Covid-19.

"What this Warp Speed award does is it pays for production of 100 million doses, which would be delivered starting in the fourth quarter of this year, and may be completed by January or February of next year," Novavax Chief Executive Stanley Erck told Reuters.

It will also cover the cost of running a large Phase III trial - the final stage of human testing, which could begin as early as October.

The announcement follows a $456 million investment in Johnson & Johnson's vaccine candidate in March, a $486 million award to Moderna Inc in April, and up to $1.2 billion in support in May for AstraZeneca's vaccine being developed with Oxford University. The US government also awarded Emergent Biosolutions $628 million to expand domestic manufacturing capacity for a potential coronavirus vaccine and drugs to treat Covid-19.

A safe and effective vaccine is seen as critical to ending a pandemic that has claimed over half a million lives globally, about a quarter of them in the United States.

The Gaithersburg, Maryland-based company is somewhat of a dark horse in the race for a coronavirus vaccine. The company was not on the list of vaccine finalists for Warp Speed reported by the New York Times that included Moderna, AstraZeneca, Pfizer Inc, J&J, and Merck & Co.

In May, Novavax got an additional $388 million in funding for Covid-19 vaccine development from the Coalition for Epidemic Preparedness Innovations (CEPI) after a $4 million investment in March. In June, the US Department of Defense awarded the company $60 million to support manufacturing of 10 million doses of its vaccine in 2020.

'A BIG SCALE UP'

The company is in the process of transferring its vaccine technology to an unnamed contract manufacturer that has two large manufacturing facilities, the CEO said. That is in addition to the work being done by Emergent Biosolutions, which is making doses to supply the company's smaller early and midstage clinical trials.

The Novavax vaccine works in conjunction with an adjuvant - a substance that boosts the immune response to help the body build a robust defense against the virus.

Currently, Novavax makes its adjuvant in Sweden. The company is building up US manufacturing capacity for its adjuvant "so that we can make upwards of a billion doses of adjuvant in the United States," he said.

Novavax did not start human safety trials until late May. One reason for the delay is that the vaccine is grown in insect cells, a process that can take 30 days before company scientists can start purifying it and making it in bulk.

"You lose a month or so there, but I don't think we're behind because our data," he said, referring to animal data showing a strong immune response and high levels of virus-killing antibodies.

Erck said Novavax expects results of its Phase I safety trial within the next week or so. The company aims to start midstage trials in August or September, with Phase III testing starting in October, he added.

By early next year, the company expects to be able to make 50 million doses a month in the United States.

"It's a big scale up in a few different manufacturing sites in the United States," Erck said. "What it leaves us with is the capacity of making many more doses in the US in 2021."

Novavax also has a manufacturing plant in the Czech Republic and hopes to have two other plants in Europe and one in Asia, Erck said. The company is also working with a manufacturer in India. The aim there is to make more than 100 million doses a month, he said.

Coronavirus Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Power price, subsidy to rise as govt has to pay producers at latest dollar rate
    Power price, subsidy to rise as govt has to pay producers at latest dollar rate
  • Photo: BSS
    BB formulates digital payment policies with quick refund, penalty provisions
  • Obaidul Quader speaking at a peace and development rally arranged by the Dhaka District Awami League in Keraniganj this afternoon (26 September), protesting terrorism, militancy, anarchy, ill-politics and anti-state conspiracy of the BNP and Jamaat. Photo: Collected
    Sheikh Hasina cannot be stopped through visa policy, sanctions: Quader at rally

MOST VIEWED

  • US dollar banknotes are seen in this illustration taken on 10 March 2023. Photo: Reuters
    Taka weakens even further
  • The Fitch Ratings logo is seen at their offices at Canary Wharf financial district in London,Britain, March 3, 2016. REUTERS/Reinhard Krause
    Fitch now rates Bangladesh's foreign debt outlook negative
  • Experts say Dhaka has at least 18 times more than the population it can actually support. Photo: Rajib Dhar
    DAP relaxes floor area ratio, planners raise concerns over Dhaka's livability
  • Dollar rates raised to Tk110 for remitters, exporters
    Dollar rates raised to Tk110 for remitters, exporters
  • Why Biman struggles to overcome pilot shortage
    Why Biman struggles to overcome pilot shortage
  • Record Bangladeshis hired in Italy this year, $800m sent home
    Record Bangladeshis hired in Italy this year, $800m sent home

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit
  • Britain approves Valneva's easy-to-store Covid shot
  • More funds incoming from dev partners for vaccine purchase

Features

India-Canada clash should be a wakeup call

India-Canada clash should be a wakeup call

22h | Panorama
It is highly unlikely that inflation rate is going to come down soon. PHOTO: TBS

No more central bank loans to the govt: Will it be enough to curb inflation?

22h | Panorama
Why Bangladeshi patients flock to India

Why Bangladeshi patients flock to India

22h | Panorama
Nooruddin Complex: Of childhood, dreams and a sense of community

Nooruddin Complex: Of childhood, dreams and a sense of community

22h | Habitat

More Videos from TBS

How dependent is Canada's economy on India?

How dependent is Canada's economy on India?

11h | TBS World
IMEC; Is the main objective to stop China?

IMEC; Is the main objective to stop China?

10h | TBS World
Why Biman struggles to overcome pilot shortage

Why Biman struggles to overcome pilot shortage

14h | TBS Insight
Global Finance's report card: Bangladesh Bank governor got ‘D’

Global Finance's report card: Bangladesh Bank governor got ‘D’

13h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]